Correcting common errors in identifying cancer-specific serum peptide signatures - Wikidata - wikimedia - TriplyDB

Correcting common errors in identifying cancer-specific serum peptide signatures

Correcting common errors in identifying cancer-specific serum peptide signatures

http://www.wikidata.org/entity/Q33221189

about

Solid-phase extraction strategies to surmount body fluid sample complexity in high-throughput mass spectrometry-based proteomics Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays Proteomics and mass spectrometry for cancer biomarker discovery Evaluating the effects of preanalytical variables on the stability of the human plasma proteome Quality measures of imaging mass spectrometry aids in revealing long-term striatal protein changes induced by neonatal exposure to the cyanobacterial toxin β-N-methylamino-L-alanine (BMAA)Processing MALDI Mass Spectra to Improve Mass Spectral Direct Tissue Analysis Normalization in MALDI-TOF imaging datasets of proteins: practical considerations.Bayesian analysis of mass spectrometry proteomic data using wavelet-based functional mixed models.Differential exoprotease activities confer tumor-specific serum peptidome patterns Automated serum peptide profiling.Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations.Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.A robust biomarker discovery pipeline for high-performance mass spectrometry data.A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery.Serum biomarker profiling by solid-phase extraction with particle-embedded micro tips and matrix-assisted laser desorption/ionization mass spectrometry Precision enhancement of MALDI-TOF MS using high resolution peak detection and label-free alignment Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data.Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study BioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry.Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome.HDL in humans with cardiovascular disease exhibits a proteomic signature.High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model.Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead.Enabling individualized therapy through nanotechnology Biomarkers discovery by peptide and protein profiling in biological fluids based on functionalized magnetic beads purification and mass spectrometry.Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.Primary study of lymph node metastasis-related serum biomarkers in breast cancer.Functional protease profiling for diagnosis of malignant disease.Species determination of Culicoides biting midges via peptide profiling using matrix-assisted laser desorption ionization mass spectrometry.Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever.Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers.Evaluation of inter-day and inter-individual variability of tear peptide/protein profiles by MALDI-TOF MS analyses.Proteomic serum biomarkers and their potential application in cancer screening programs.Genomics and proteomics of lung disease: conference summary.Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.O-glycan profiling of serum glycan for potential renal cancer biomarkers.

P2860

Q28650185-3C8F08E0-0C05-40B4-BDA1-26DA1D837B9C Q28743469-220223A2-34A5-4664-83EB-A2D352FB39F2 Q28766969-3308A7EC-103A-4FF1-8B2F-97EF90A7AF71 Q30372676-BB20F8CA-C06B-49FB-A0B6-0140AF516762 Q30444494-F6C2DAF5-C4C5-4DB2-A32A-E98B28BD45DB Q30498661-565DB2C9-81E6-43A1-97C9-80FACE2C1120 Q31004927-A59327A7-87B1-4683-B4D0-523F93869772 Q31130667-498BD313-C0D0-4D83-AADF-41BE7ECF591E Q33230965-F118934E-1ACE-49E4-BC9C-B72E1DBD82A5 Q33280949-80D528BF-AB9A-4E9A-AEE4-A12C4BA504BC Q33282300-979B4B44-E110-44DF-9631-67D7BD1D1EF7 Q33295308-9E24824B-B035-49EE-8A47-5DDBF0A84F2F Q33302448-D38724B4-7D3E-4AEF-9FA1-1D97766D8EAD Q33305170-717D679F-6DAB-4EE2-9830-C38DB0135462 Q33322569-785EB855-9592-4B8A-BADF-E5A4B5327ECB Q33323706-C1B79F75-6463-4B5C-8E8C-DA2BECB82933 Q33392137-32738F37-B982-4993-B9E3-87CCC530130C Q33400847-B618853B-254E-46B6-81E9-2DD5701AA9F9 Q33409779-CEBB2806-CAAB-4247-94F5-0EBEBA049065 Q33439145-D06B8F79-ED4B-458F-88D9-F2766F5AB14D Q33518743-E9705E56-83C7-4F63-A5D8-4829EF7DF700 Q33544033-BC8F5C22-3BA0-4215-BEC4-362F9424DE9F Q33579375-62D5B592-F33C-417E-ACBC-822AFA852D60 Q33622478-4B2D4AA4-C3A0-4CD6-9B59-87331C44AB6A Q33764534-ADC92C28-4780-4389-A06F-5362F4A0CA77 Q33891197-13294166-BE2B-4409-B512-2A80491199BD Q33917755-95CDE93B-65BE-45CE-B68A-EF12FF401A9E Q33962458-C8558704-96E8-4EFA-BA40-6C0365248C0D Q34003835-F869DDF5-591E-4B9D-88AD-083C5F652B43 Q34018095-D48EC8BB-336C-4618-92DC-4807887A92A6 Q34037335-D0DE4873-8415-45AA-861F-84F02B1AACD1 Q34116114-44E616C5-E819-4C66-ABAF-5076FB025822 Q34151055-4FD87BDA-B2C7-4D0D-A81F-DA4DB5031D9E Q34178965-40C12652-09D5-4577-B10F-4DD31FE47036 Q34268788-D619D923-FB6A-4AFE-94B0-7F7596D82B4B Q34318147-91387D99-E131-4B0F-A9BD-295A1294FD2D Q34395996-EE33C9C9-CF2D-4F0F-909C-0F6BCF6A2852 Q34420043-92BF9E7D-4846-4390-8658-DAD879576A85 Q34468372-5E5D1EDC-E199-4177-8A32-2CD4673CE4D4 Q34777759-8A6EF813-85BA-44A2-BC09-FB9DBD4A4931

P2860

Correcting common errors in identifying cancer-specific serum peptide signatures

http://www.wikidata.org/entity/Q33221189

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Correcting common errors in identifying cancer-specific serum peptide signatures

@ast

Correcting common errors in identifying cancer-specific serum peptide signatures

@en

type

label

Correcting common errors in identifying cancer-specific serum peptide signatures

@ast

Correcting common errors in identifying cancer-specific serum peptide signatures

@en

prefLabel

Correcting common errors in identifying cancer-specific serum peptide signatures

@ast

Correcting common errors in identifying cancer-specific serum peptide signatures

@en

P1433

Q33221189-ACABF4B5-DD50-477F-BFDC-75835FDAA609

P1476

Q33221189-9E18708E-8AF5-4E64-AE3E-63E1B8515446

P2093

Q33221189-31458C26-21CD-46F4-BBE8-E3FD4248D438

Q33221189-48864DBF-3D4D-4DB5-AA18-7BDDA9944E50

Q33221189-87A9937E-3EAD-4F9E-B11E-139EECC5BF97

Q33221189-A6CF9A3C-DFE2-4CF2-9478-C678B10B5F50

Q33221189-BBA43B18-7A78-4ABC-99F5-287A26E96A46

Q33221189-D0E40027-B716-4FA5-918F-9ED9761A4FB0

Q33221189-E7D6C19F-8AE4-4338-8C0C-0E48BB5AABC7

Q33221189-F8DF74F8-C0A2-4706-BEFA-17C29B1DBDBE

P2860

Q33221189-1A1A11DC-5C5B-48CC-965A-7DCC95B300D8

Q33221189-218DFAB8-54EE-4EBF-B98F-E203BD176D61

Q33221189-38650CA8-A1E0-4310-9D1A-FBF6443C0DCC

Q33221189-4309B93F-3CED-4993-9588-390334601B22

Q33221189-5C4D695B-454E-41A5-A12D-AA4ADC92FC54

Q33221189-6034E74B-A40C-4C3C-9372-BDFEB8759540

Q33221189-694B4520-AA1C-4F57-9A97-E61A3E5399E7

Q33221189-79BF29A3-87E6-4B2E-956D-01BE9C7F2051

Q33221189-89DF6DFD-7EE3-445F-A95D-88A30575CDB9

Q33221189-8CC59A60-3853-4D2A-A579-FC5AA69B2DA4

P304

Q33221189-59995D11-73A3-40A8-BA9A-780455F4586F

P31

Q33221189-59AAC97E-DF4A-4338-B092-9096B7CC414D

P356

Q33221189-374E1777-7019-46AD-BF59-28BED6275586

P433

Q33221189-F42FC541-CA87-4E97-A218-83C8EA3A6224

P478

Q33221189-40E2CD08-896E-4D41-8AE2-F8D7EC5EA9F4

P50

Q33221189-CB8F7E66-5FDD-4465-8D07-4F8E26E606AA

P577

Q33221189-1524BE29-913B-45D1-B95B-C58F3CA165F6

P5875

Q33221189-A3D99DBE-329F-4C94-A733-FF1B05C067A1

P698

Q33221189-35572720-0B31-4F30-AE36-92112462999B

P932

Q33221189-66032B3C-DE25-462D-BA00-DE2EF31A73C6

P356

P1433

Journal of Proteome Research

P1476

Correcting common errors in identifying cancer-specific serum peptide signatures

@en

P2093

Carlos A Chaparro

http://www.w3.org/2001/XMLSchema#string

John Philip

http://www.w3.org/2001/XMLSchema#string

Josep Villanueva

http://www.w3.org/2001/XMLSchema#string

Lin DeNoyer

http://www.w3.org/2001/XMLSchema#string

Martin Fleisher

http://www.w3.org/2001/XMLSchema#string

Ricardo Toledo-Crow

http://www.w3.org/2001/XMLSchema#string

Richard J Robbins

http://www.w3.org/2001/XMLSchema#string

Yongbiao Li

http://www.w3.org/2001/XMLSchema#string

P2860

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer

Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments.

Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations.

A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.

Use of proteomic patterns in serum to identify ovarian cancer.

Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data.

Protocols for disease classification from mass spectrometry data.

Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.

Detection of cancer-specific markers amid massive mass spectral data.

Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.

P304

1060-1072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/PR050034B

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7677354

http://www.w3.org/2001/XMLSchema#string

P698

16083255

http://www.w3.org/2001/XMLSchema#string

P932

1852495

http://www.w3.org/2001/XMLSchema#string